<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01760187</url>
  </required_header>
  <id_info>
    <org_study_id>AEGR-733-023</org_study_id>
    <secondary_id>2012-004220-37</secondary_id>
    <nct_id>NCT01760187</nct_id>
  </id_info>
  <brief_title>Phase I Study of the Safety, Tolerability, PK &amp; PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Lomitapide in Japanese and Caucasian Volunteers With Elevated Low-density-lipoprotein(LDL-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Richmond Pharmacology Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and
      multiple ascending dose (MAD) study of orally administered lomitapide in healthy male
      Japanese and Caucasian subjects with elevated LDL-C. The purpose for this study is to
      evaluate the PK and PD of lomitapide in Japanese subjects as compared to Caucasian subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2012</start_date>
  <completion_date type="Actual">June 3, 2013</completion_date>
  <primary_completion_date type="Actual">June 3, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax for Lomitapide</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Maximum observed plasma concentration for lomitapide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for Lomitapide</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Time to maximum observed concentration for lomitapide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t for Lomitapide</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for lomitapide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ for Lomitapide</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Area under the plasma concentration versus time curve from zero to infinity for lomitapide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 for Lomitapide</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Apparent terminal elimination half-life for lomitapide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Lomitapide</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Maximum observed plasma concentration for lomitapide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for Lomitapide</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Time to maximum observed concentration for lomitapide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t for Lomitapide</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for lomitapide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 for Lomitapide</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Apparent terminal elimination half-life for lomitapide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax for M1</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Maximum observed plasma concentration for M1 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for M1</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Time to maximum observed concentration for M1 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t for M1</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M1 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ for M1</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Area under the plasma concentration versus time curve from zero to infinity for M1 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for M1</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Apparent terminal elimination half-life for M1 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for M3</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Maximum observed plasma concentration for M3 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for M3</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Time to maximum observed concentration for M3 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t for M3</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M3 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ for M3</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Area under the plasma concentration versus time curve from zero to infinity for M3 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for M3</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
    <description>Apparent terminal elimination half-life for M3 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for M1</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Maximum observed plasma concentration for M1 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for M1</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Time to maximum observed concentration for M1 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t for M1</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M1 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for M1</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Apparent terminal elimination half-life for M1 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for M3</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Maximum observed plasma concentration for M3 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for M3</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Time to maximum observed concentration for M3 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t for M3</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M3 metabolite of lomitapide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for M3</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
    <description>Apparent terminal elimination half-life for M3 metabolite of lomitapide</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 Japanese and 12 Caucasian subjects. 10 out of 12 will receive 10 mg lomitapide and 2 will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 20 mg lomitapide and 2 will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 40 mg lomitapide and 2 will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 60 mg lomitapide and 2 will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomitapide</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Subject is a healthy male or female, Caucasian or Japanese, aged 20 - 45 years,
             inclusive, at screening.

             2. Subject has a BMI of 18.5 - 30 kg/m2 inclusive at screening.

             3. Subjects must have a screening LDL-C measurement and the mean of Day 5 and Day 6
             measurements greater than or equal to 110mg/dL.

             4. Subjects must agree to use acceptable methods of contraception (details provided in
             the protocol)

             5. Subjects must be capable of understanding and complying with the requirements of
             the protocol and must have signed the informed consent form prior to undergoing any
             study-related procedures.

        Exclusion Criteria:

          1. Subject has a clinically significant disease or any condition or disease that might
             affect drug absorption, distribution or excretion.

          2. Any clinically significant abnormal laboratory, vital signs or other safety findings
             as determined by medical history, physical examination or other evaluations conducted
             at screening or on admission.

          3. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) which
             in the opinion of the Investigator is clinically relevant or will interfere with the
             ECG analysis.

          4. History or current evidence of any clinically relevant cardiovascular, pulmonary,
             hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic,
             neurological, psychiatric or other disease.

          5. Positive results in any of the serology tests for Hepatitis B Surface Antigen (HbsAg),
             anti-Hepatitis core antibody (anti-HBc Ig G [and anti-HBc IgM if IgG is positive],
             Hepatitis C antibodies (anti-HCV), and HIV 1 and 2 antibodies, (anti-HIV 1/2) at
             screening.

          6. Confirmed positive results from urine drug screen or from the alcohol breath test at
             screening and on admission (Day -1).

          7. History or clinical evidence of alcohol or drug abuse.

          8. Mentally handicapped.

          9. Participation in a drug trial within 90 days prior to first drug administration.

         10. Use of any medication (including over-the-counter (OTC) medication) within 2 weeks
             prior to admission (Day -1) or within less than 10 times the elimination half-life of
             the respective drug, or anticipated concomitant medication during the treatment
             periods.

         11. Use of any substance inhibiting CYP3A4 enzymes within 2 weeks prior to admission (Day
             -1).

         12. Donation of more than 500 mL of blood within 90 days prior to drug administration.

         13. Subjects who smoke more than 10 cigarettes or equivalent amount of tobacco per day
             and/or who cannot stop smoking for the duration of the study whilst in the CPU.

         14. Treatment with herbal supplements during the 7 days prior to dosing, or use of
             vitamins during 48 hours prior to admission (Day -1).

         15. Any circumstances or conditions, which, in the opinion of the PI, may affect full
             participation in the trial or compliance with the protocol.

         16. Legal incapacity or limited legal capacity at screening.

         17. Subjects who are vegetarians, vegans or have any dietary restrictions conflicting with
             the study standardised menus.

         18. If female, subject was pregnant or lactating (females of child bearing potential must
             have negative pregnancy tests at screening and admission).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Lorch, MD FRCA FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Pharmacology Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richmond Pharmacology Ltd</name>
      <address>
        <city>Croydon</city>
        <state>Surrey</state>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 21, 2012</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <results_first_submitted>June 23, 2015</results_first_submitted>
  <results_first_submitted_qc>November 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2018</results_first_posted>
  <last_update_submitted>November 16, 2018</last_update_submitted>
  <last_update_submitted_qc>November 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>10 Japanese and 10 Caucasian subjects will receive 10 mg lomitapide.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>6 Japanese and 6 Caucasian subjects will receive 20 mg lomitapide.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>6 Japanese and 6 Caucasian subjects will receive 40 mg lomitapide.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4</title>
          <description>6 Japanese and 6 Caucasian subjects will receive 60 mg lomitapide.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>8 Japanese and 8 Caucasian subjects will receive placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo - Japanese Patients</title>
          <description>8 Japanese patients will receive placebo, across the cohorts.
(2 at each cohort)</description>
        </group>
        <group group_id="B2">
          <title>Placebo - Caucasian Patients</title>
          <description>8 Caucasian patients will receive placebo, across the cohorts.
(2 at each cohort)</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1- Japanese Patients</title>
          <description>10 Japanese subjects will receive 10 mg of lomitapide.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 1 - Caucasian Patients</title>
          <description>10 Caucasian subjects will receive 10 mg of lomitapide.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 2 - Japanese Patients</title>
          <description>6 Japanese subjects will receive 20 mg of lomitapide.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 2 - Caucasian Patients</title>
          <description>6 Caucasian subjects will receive 20 mg of lomitapide.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 3 - Japanese Patients</title>
          <description>6 Japanese subjects will receive 40 mg of lomitapide.</description>
        </group>
        <group group_id="B8">
          <title>Cohort 3 - Caucasian Patients</title>
          <description>6 Caucasian subjects will receive 40 mg of lomitapide.</description>
        </group>
        <group group_id="B9">
          <title>Cohort 4 - Japanese Patients</title>
          <description>6 Japanese subjects will receive 60 mg of lomitapide.</description>
        </group>
        <group group_id="B10">
          <title>Cohort 4 - Caucasian Patients</title>
          <description>6 Caucasian subjects will receive 60 mg of lomitapide.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="6.0"/>
                    <measurement group_id="B2" value="33.6" spread="7.3"/>
                    <measurement group_id="B3" value="33.8" spread="6.0"/>
                    <measurement group_id="B4" value="31.2" spread="6.6"/>
                    <measurement group_id="B5" value="32.2" spread="5.4"/>
                    <measurement group_id="B6" value="36.0" spread="7.5"/>
                    <measurement group_id="B7" value="32.5" spread="4.6"/>
                    <measurement group_id="B8" value="31.2" spread="9.7"/>
                    <measurement group_id="B9" value="30.2" spread="5.4"/>
                    <measurement group_id="B10" value="37.7" spread="3.4"/>
                    <measurement group_id="B11" value="33.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Lomitapide</title>
        <description>Maximum observed plasma concentration for lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Lomitapide</title>
          <description>Maximum observed plasma concentration for lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.570" spread="0.285"/>
                    <measurement group_id="O2" value="0.436" spread="0.166"/>
                    <measurement group_id="O3" value="1.70" spread="0.49"/>
                    <measurement group_id="O4" value="1.01" spread="0.17"/>
                    <measurement group_id="O5" value="3.93" spread="0.75"/>
                    <measurement group_id="O6" value="3.00" spread="1.52"/>
                    <measurement group_id="O7" value="8.29" spread="3.44"/>
                    <measurement group_id="O8" value="5.75" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for Lomitapide</title>
        <description>Time to maximum observed concentration for lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Lomitapide</title>
          <description>Time to maximum observed concentration for lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="O3" value="9" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O4" value="6" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="O5" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O6" value="5" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O7" value="6" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O8" value="5" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t for Lomitapide</title>
        <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t for Lomitapide</title>
          <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="13.0"/>
                    <measurement group_id="O2" value="27.5" spread="11.0"/>
                    <measurement group_id="O3" value="63.0" spread="16.0"/>
                    <measurement group_id="O4" value="54.2" spread="9.6"/>
                    <measurement group_id="O5" value="152" spread="48"/>
                    <measurement group_id="O6" value="123" spread="53"/>
                    <measurement group_id="O7" value="238" spread="84"/>
                    <measurement group_id="O8" value="241" spread="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ for Lomitapide</title>
        <description>Area under the plasma concentration versus time curve from zero to infinity for lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>AUC0-∞ and t1/2 were not calculated for 3 subjects in the Japanese 10mg arm because the estimated t1/2 was being much longer than half of the total sampling time.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ for Lomitapide</title>
          <description>Area under the plasma concentration versus time curve from zero to infinity for lomitapide</description>
          <population>AUC0-∞ and t1/2 were not calculated for 3 subjects in the Japanese 10mg arm because the estimated t1/2 was being much longer than half of the total sampling time.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" spread="16.7"/>
                    <measurement group_id="O2" value="35.9" spread="15.3"/>
                    <measurement group_id="O3" value="68.6" spread="17.4"/>
                    <measurement group_id="O4" value="64.7" spread="14.7"/>
                    <measurement group_id="O5" value="168" spread="59"/>
                    <measurement group_id="O6" value="133" spread="58"/>
                    <measurement group_id="O7" value="251" spread="89"/>
                    <measurement group_id="O8" value="260" spread="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 for Lomitapide</title>
        <description>Apparent terminal elimination half-life for lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>AUC0-∞ and t1/2 were not calculated for 3 subjects in the Japanese 10mg arm because the estimated t1/2 was being much longer than half of the total sampling time.</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 for Lomitapide</title>
          <description>Apparent terminal elimination half-life for lomitapide</description>
          <population>AUC0-∞ and t1/2 were not calculated for 3 subjects in the Japanese 10mg arm because the estimated t1/2 was being much longer than half of the total sampling time.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" spread="5.6"/>
                    <measurement group_id="O2" value="82.8" spread="5.9"/>
                    <measurement group_id="O3" value="50.5" spread="2.6"/>
                    <measurement group_id="O4" value="64.3" spread="20.6"/>
                    <measurement group_id="O5" value="58.8" spread="13.3"/>
                    <measurement group_id="O6" value="56.2" spread="7.1"/>
                    <measurement group_id="O7" value="44.9" spread="5.7"/>
                    <measurement group_id="O8" value="51.5" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Lomitapide</title>
        <description>Maximum observed plasma concentration for lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Lomitapide</title>
          <description>Maximum observed plasma concentration for lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="0.88"/>
                    <measurement group_id="O2" value="3.31" spread="2.91"/>
                    <measurement group_id="O3" value="5.96" spread="2.79"/>
                    <measurement group_id="O4" value="4.35" spread="1.07"/>
                    <measurement group_id="O5" value="19.7" spread="6.2"/>
                    <measurement group_id="O6" value="13.8" spread="5.1"/>
                    <measurement group_id="O7" value="29.6" spread="11.1"/>
                    <measurement group_id="O8" value="24.6" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for Lomitapide</title>
        <description>Time to maximum observed concentration for lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Lomitapide</title>
          <description>Time to maximum observed concentration for lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O7" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O8" value="4" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t for Lomitapide</title>
        <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t for Lomitapide</title>
          <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" spread="14.1"/>
                    <measurement group_id="O2" value="44.5" spread="29.0"/>
                    <measurement group_id="O3" value="91.3" spread="29.5"/>
                    <measurement group_id="O4" value="74.4" spread="18.8"/>
                    <measurement group_id="O5" value="263" spread="64"/>
                    <measurement group_id="O6" value="204" spread="79"/>
                    <measurement group_id="O7" value="388" spread="86"/>
                    <measurement group_id="O8" value="403" spread="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2 for Lomitapide</title>
        <description>Apparent terminal elimination half-life for lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 for Lomitapide</title>
          <description>Apparent terminal elimination half-life for lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6" spread="10.1"/>
                    <measurement group_id="O2" value="57.6" spread="8.9"/>
                    <measurement group_id="O3" value="56.1" spread="9.9"/>
                    <measurement group_id="O4" value="53.3" spread="8.5"/>
                    <measurement group_id="O5" value="49.7" spread="11.3"/>
                    <measurement group_id="O6" value="44.8" spread="6.4"/>
                    <measurement group_id="O7" value="48.9" spread="9.9"/>
                    <measurement group_id="O8" value="46.5" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax for M1</title>
        <description>Maximum observed plasma concentration for M1 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for M1</title>
          <description>Maximum observed plasma concentration for M1 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.23"/>
                    <measurement group_id="O2" value="1.02" spread="0.23"/>
                    <measurement group_id="O3" value="2.27" spread="0.54"/>
                    <measurement group_id="O4" value="1.86" spread="0.54"/>
                    <measurement group_id="O5" value="4.18" spread="1.22"/>
                    <measurement group_id="O6" value="4.20" spread="1.72"/>
                    <measurement group_id="O7" value="7.43" spread="1.88"/>
                    <measurement group_id="O8" value="5.53" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax for M1</title>
        <description>Time to maximum observed concentration for M1 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for M1</title>
          <description>Time to maximum observed concentration for M1 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O3" value="5" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O4" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O5" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O6" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O7" value="6" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O8" value="6" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t for M1</title>
        <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M1 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t for M1</title>
          <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M1 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="9.7"/>
                    <measurement group_id="O2" value="32.1" spread="7.9"/>
                    <measurement group_id="O3" value="64.1" spread="15.6"/>
                    <measurement group_id="O4" value="56.7" spread="18.6"/>
                    <measurement group_id="O5" value="134" spread="37"/>
                    <measurement group_id="O6" value="129" spread="57"/>
                    <measurement group_id="O7" value="199" spread="64"/>
                    <measurement group_id="O8" value="177" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞ for M1</title>
        <description>Area under the plasma concentration versus time curve from zero to infinity for M1 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ for M1</title>
          <description>Area under the plasma concentration versus time curve from zero to infinity for M1 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" spread="10.1"/>
                    <measurement group_id="O2" value="34.0" spread="8.3"/>
                    <measurement group_id="O3" value="65.7" spread="15.9"/>
                    <measurement group_id="O4" value="59.1" spread="19.5"/>
                    <measurement group_id="O5" value="138" spread="39"/>
                    <measurement group_id="O6" value="132" spread="58"/>
                    <measurement group_id="O7" value="204" spread="67"/>
                    <measurement group_id="O8" value="183" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 for M1</title>
        <description>Apparent terminal elimination half-life for M1 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 for M1</title>
          <description>Apparent terminal elimination half-life for M1 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" spread="11.3"/>
                    <measurement group_id="O2" value="44.0" spread="14.3"/>
                    <measurement group_id="O3" value="35.9" spread="8.7"/>
                    <measurement group_id="O4" value="35.9" spread="6.0"/>
                    <measurement group_id="O5" value="41.5" spread="4.3"/>
                    <measurement group_id="O6" value="36.3" spread="7.9"/>
                    <measurement group_id="O7" value="39.4" spread="3.4"/>
                    <measurement group_id="O8" value="43.6" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax for M3</title>
        <description>Maximum observed plasma concentration for M3 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for M3</title>
          <description>Maximum observed plasma concentration for M3 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="4.1"/>
                    <measurement group_id="O2" value="14.2" spread="4.8"/>
                    <measurement group_id="O3" value="35.3" spread="8.2"/>
                    <measurement group_id="O4" value="20.0" spread="5.8"/>
                    <measurement group_id="O5" value="55.7" spread="18.3"/>
                    <measurement group_id="O6" value="50.9" spread="24.7"/>
                    <measurement group_id="O7" value="83.9" spread="34.5"/>
                    <measurement group_id="O8" value="67.7" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax for M3</title>
        <description>Time to maximum observed concentration for M3 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for M3</title>
          <description>Time to maximum observed concentration for M3 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O5" value="3" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O6" value="2" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O7" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O8" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t for M3</title>
        <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M3 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t for M3</title>
          <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M3 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265" spread="53"/>
                    <measurement group_id="O2" value="185" spread="86"/>
                    <measurement group_id="O3" value="486" spread="145"/>
                    <measurement group_id="O4" value="263" spread="115"/>
                    <measurement group_id="O5" value="760" spread="169"/>
                    <measurement group_id="O6" value="824" spread="355"/>
                    <measurement group_id="O7" value="1410" spread="675"/>
                    <measurement group_id="O8" value="1170" spread="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞ for M3</title>
        <description>Area under the plasma concentration versus time curve from zero to infinity for M3 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ for M3</title>
          <description>Area under the plasma concentration versus time curve from zero to infinity for M3 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276" spread="55"/>
                    <measurement group_id="O2" value="196" spread="91.2"/>
                    <measurement group_id="O3" value="501" spread="147"/>
                    <measurement group_id="O4" value="274" spread="119"/>
                    <measurement group_id="O5" value="780" spread="171"/>
                    <measurement group_id="O6" value="839" spread="361"/>
                    <measurement group_id="O7" value="1430" spread="693"/>
                    <measurement group_id="O8" value="1200" spread="551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 for M3</title>
        <description>Apparent terminal elimination half-life for M3 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 for M3</title>
          <description>Apparent terminal elimination half-life for M3 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" spread="11.6"/>
                    <measurement group_id="O2" value="56.9" spread="10.2"/>
                    <measurement group_id="O3" value="53.1" spread="12.9"/>
                    <measurement group_id="O4" value="51.3" spread="6.4"/>
                    <measurement group_id="O5" value="50.5" spread="14.9"/>
                    <measurement group_id="O6" value="39.4" spread="6.1"/>
                    <measurement group_id="O7" value="47.0" spread="7.4"/>
                    <measurement group_id="O8" value="43.8" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax for M1</title>
        <description>Maximum observed plasma concentration for M1 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for M1</title>
          <description>Maximum observed plasma concentration for M1 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="0.44"/>
                    <measurement group_id="O2" value="2.15" spread="0.53"/>
                    <measurement group_id="O3" value="4.36" spread="0.88"/>
                    <measurement group_id="O4" value="4.24" spread="1.30"/>
                    <measurement group_id="O5" value="9.98" spread="4.13"/>
                    <measurement group_id="O6" value="10.7" spread="3.6"/>
                    <measurement group_id="O7" value="13.5" spread="3.4"/>
                    <measurement group_id="O8" value="12.6" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax for M1</title>
        <description>Time to maximum observed concentration for M1 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for M1</title>
          <description>Time to maximum observed concentration for M1 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O2" value="6" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O3" value="6" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O4" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O6" value="6" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O7" value="6" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O8" value="4" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t for M1</title>
        <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M1 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t for M1</title>
          <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M1 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="8.5"/>
                    <measurement group_id="O2" value="36.1" spread="8.5"/>
                    <measurement group_id="O3" value="73.7" spread="14.4"/>
                    <measurement group_id="O4" value="75.3" spread="25.9"/>
                    <measurement group_id="O5" value="180" spread="78"/>
                    <measurement group_id="O6" value="176" spread="58"/>
                    <measurement group_id="O7" value="230" spread="71"/>
                    <measurement group_id="O8" value="223" spread="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 for M1</title>
        <description>Apparent terminal elimination half-life for M1 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 for M1</title>
          <description>Apparent terminal elimination half-life for M1 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" spread="9.0"/>
                    <measurement group_id="O2" value="41.9" spread="7.5"/>
                    <measurement group_id="O3" value="41.6" spread="8.5"/>
                    <measurement group_id="O4" value="39.7" spread="4.5"/>
                    <measurement group_id="O5" value="41.0" spread="6.6"/>
                    <measurement group_id="O6" value="36.0" spread="1.7"/>
                    <measurement group_id="O7" value="43.5" spread="7.8"/>
                    <measurement group_id="O8" value="41.2" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax for M3</title>
        <description>Maximum observed plasma concentration for M3 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for M3</title>
          <description>Maximum observed plasma concentration for M3 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="9.3"/>
                    <measurement group_id="O2" value="24.1" spread="7.9"/>
                    <measurement group_id="O3" value="56.4" spread="15.0"/>
                    <measurement group_id="O4" value="35.2" spread="18.8"/>
                    <measurement group_id="O5" value="76.3" spread="26.7"/>
                    <measurement group_id="O6" value="86.4" spread="27.1"/>
                    <measurement group_id="O7" value="129" spread="35"/>
                    <measurement group_id="O8" value="126" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax for M3</title>
        <description>Time to maximum observed concentration for M3 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for M3</title>
          <description>Time to maximum observed concentration for M3 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O3" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O7" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O8" value="2" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t for M3</title>
        <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M3 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t for M3</title>
          <description>Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M3 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335" spread="84"/>
                    <measurement group_id="O2" value="239" spread="90"/>
                    <measurement group_id="O3" value="617" spread="163"/>
                    <measurement group_id="O4" value="386" spread="183"/>
                    <measurement group_id="O5" value="891" spread="259"/>
                    <measurement group_id="O6" value="1150" spread="462"/>
                    <measurement group_id="O7" value="1640" spread="664"/>
                    <measurement group_id="O8" value="1640" spread="767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 for M3</title>
        <description>Apparent terminal elimination half-life for M3 metabolite of lomitapide</description>
        <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27</time_frame>
        <population>All subjects with evaluable concentrations</population>
        <group_list>
          <group group_id="O1">
            <title>Japanese 10 mg</title>
            <description>Japanese Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 10 mg</title>
            <description>Caucasian Subjects who received 10 mg Lomitapide</description>
          </group>
          <group group_id="O3">
            <title>Japanese 20 mg</title>
            <description>Japanese Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O4">
            <title>Caucasian 20 mg</title>
            <description>Caucasian Subjects who received 20 mg Lomitapide</description>
          </group>
          <group group_id="O5">
            <title>Japanese 40 mg</title>
            <description>Japanese Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O6">
            <title>Caucasian 40 mg</title>
            <description>Caucasian Subjects who received 40 mg Lomitapide</description>
          </group>
          <group group_id="O7">
            <title>Japanese 60 mg</title>
            <description>Japanese Subjects who received 60 mg Lomitapide</description>
          </group>
          <group group_id="O8">
            <title>Caucasian 60 mg</title>
            <description>Caucasian Subjects who received 60 mg Lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 for M3</title>
          <description>Apparent terminal elimination half-life for M3 metabolite of lomitapide</description>
          <population>All subjects with evaluable concentrations</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4" spread="11.0"/>
                    <measurement group_id="O2" value="44.3" spread="7.2"/>
                    <measurement group_id="O3" value="40.4" spread="6.9"/>
                    <measurement group_id="O4" value="55.4" spread="11.5"/>
                    <measurement group_id="O5" value="41.6" spread="8.6"/>
                    <measurement group_id="O6" value="39.3" spread="7.6"/>
                    <measurement group_id="O7" value="54.9" spread="17.4"/>
                    <measurement group_id="O8" value="41.8" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Japanese Patients</title>
          <description>8 Japanese patients will receive placebo, across the cohorts.
(2 at each cohort)</description>
        </group>
        <group group_id="E2">
          <title>Placebo - Caucasian Patients</title>
          <description>8 Caucasian patients will receive placebo, across the cohorts.
(2 at each cohort)</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1- Japanese Patients</title>
          <description>10 Japanese subjects will receive 10 mg of lomitapide.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 1 - Caucasian Patients</title>
          <description>10 Caucasian subjects will receive 10 mg of lomitapide.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 2 - Japanese Patients</title>
          <description>6 Japanese subjects will receive 20 mg of lomitapide.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 2 - Caucasian Patients</title>
          <description>6 Caucasian subjects will receive 20 mg of lomitapide.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 3 - Japanese Patients</title>
          <description>6 Japanese subjects will receive 40 mg of lomitapide.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 3 - Caucasian Patients</title>
          <description>6 Caucasian subjects will receive 40 mg of lomitapide.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 4 - Japanese Patients</title>
          <description>6 Japanese subjects will receive 60 mg of lomitapide.</description>
        </group>
        <group group_id="E10">
          <title>Cohort 4 - Caucasian Patients</title>
          <description>6 Caucasian subjects will receive 60 mg of lomitapide.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Change of Bowel Movement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Related Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>VIITH Nerve Paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Described in the contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Long, MD - VP Clinical</name_or_title>
      <organization>Aegerion Pharmaceuticals, Inc.</organization>
      <phone>8572425142</phone>
      <email>alison.long@aegerion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

